Statements (58)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:pharmaceuticals
|
| gptkbp:approves |
gptkb:2000
gptkb:FDA |
| gptkbp:available_on |
generic
|
| gptkbp:class |
gptkb:immunotherapy
|
| gptkbp:clinical_trial |
Phase III
|
| gptkbp:clinical_use |
short-term treatment
long-term treatment |
| gptkbp:condition |
seborrheic dermatitis
eczema psoriasis |
| gptkbp:contraindication |
hypersensitivity to tacrolimus
|
| gptkbp:counseling_points |
wash hands after application
apply sparingly avoid sunlight exposure |
| gptkbp:dosage_form |
0.03% and 0.1% ointment
|
| gptkbp:drug_interactions |
live vaccines
other immunosuppressants |
| gptkbp:duration |
as needed
|
| gptkbp:formulation |
ointment
|
| https://www.w3.org/2000/01/rdf-schema#label |
Protopic
|
| gptkbp:ingredients |
gptkb:tacrolimus
|
| gptkbp:invention |
gptkb:2021
|
| gptkbp:manufacturer |
gptkb:Astellas_Pharma
|
| gptkbp:marketed_as |
gptkb:Canada
gptkb:European_Union gptkb:United_States |
| gptkbp:mechanism_of_action |
inhibits T-lymphocyte activation
|
| gptkbp:patient_education |
recognizing side effects
importance of adherence proper application technique |
| gptkbp:patient_population |
gptkb:children
adults elderly |
| gptkbp:provides_guidance_on |
not for first-line therapy
used as second-line therapy |
| gptkbp:regulatory_compliance |
approved for adult use
approved for pediatric use restricted use in certain populations |
| gptkbp:requires |
prescription only
|
| gptkbp:research |
ongoing clinical trials
long-term safety studies comparative effectiveness studies |
| gptkbp:route_of_administration |
topical
|
| gptkbp:safety_measures |
regular follow-up visits
monitor for malignancies monitor for skin infections |
| gptkbp:service_frequency |
twice daily
|
| gptkbp:side_effect |
headache
nausea skin irritation redness itching burning sensation |
| gptkbp:storage |
room temperature
|
| gptkbp:used_for |
atopic dermatitis
|
| gptkbp:bfsParent |
gptkb:Valeant_Pharmaceuticals
|
| gptkbp:bfsLayer |
6
|